Abstract: A system for utilizing wearable, wireless-connected sensors that record both IMU and EMG muscle activity for rehabilitation with kinematic monitoring is disclosed. The system runs an efficient quaternion-based complementary filter that estimates the sensor orientation while correcting for estimate drift and constraining magnetometer estimates to only influence heading. The difference in the two sensor orientations is used to estimate the joint angle, which can be further improved with joint axis estimation. Thus, successful tracking of joint angle and muscle activity in a home environment can be accomplished with the sensors and a smartphone. Further, a system utilizing these sensors may include video-capable cameras configured for capturing a video of a pose of the user, and a game framework executable by a processor in communication with the sensors and the cameras.

Abstract: A system for utilizing wearable, wireless-connected sensors that record both IMU and EMG muscle activity for rehabilitation with kinematic monitoring is disclosed. The system runs an efficient quaternion-based complementary filter that estimates the sensor orientation while correcting for estimate drift and constraining magnetometer estimates to only influence heading. The difference in the two sensor orientations is used to estimate the joint angle, which can be further improved with joint axis estimation. Thus, successful tracking of joint angle and muscle activity in a home environment can be accomplished with the sensors and a smartphone. Further, a system utilizing these sensors may include video-capable cameras configured for capturing a video of a pose of the user, and a game framework executable by a processor in communication with the sensors and the cameras.

Abstract: Various embodiments of a platform for providing electromyographic biofeedback are disclosed. The platform includes a sensor device having an IMU and electrodes for simultaneous tracking of IMU and EMG activity. The IMU and EMG data may be generated and leveraged in conjunction with a gaming application provided to a user while engaged to the sensor device to provide biofeedback therapy for rehabilitation.

Abstract: A compound of formula (1), wherein: R5 is hydrogen, C1-4alkyl, R6CH2— or R6C(O)—; R6 is aryl, heteroaryl, heterocyclyl, aminoC3-6alkyl, N-(C1-4alkyl)aminoC3-6alkyl, NN-(diC1-4alkyl)aminoC3-6alkyl, or R7; wherein the aryl, heteroaryl or heterocyclyl rings may be optionally substituted with up to three substituents independently selected from nitro, C1-4alkyl, C1-4alkoxy, halo, (C1-4alkyl)sulfanyl, C1-4alkoxycarbonyl, N-(C1-4alkyl)carbamoyl, NN-(diC1-4alkyl)carbamoyl, N-(C1-4alkyl)amino or NN-(diC1-4alkyl)amino; wherein R7 is either a group or formula (2) or formula (3); and wherein L1, L2, L3, L4, R1, R2, R3, R4, R8, R9, R10, R11, R12, R13, A1, n, p, q, r and s are as defined herein. The compounds of formula (1) inhibit the interactions between MDM2 and p53 and may be useful in the treatment of cancers.

Abstract: Novel peptide derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing them are useful in treating MHC class II dependent T-cell method autoimmune or inflammatory diseases, such as rheumatoid arthritis.

Abstract: The invention relates to adsorbing chemical samples onto inert carriers to form highly stable free flowing solid for long term storage in, for example, a proprietary compound collection.

Abstract: Novel peptide derivatives, pharmaceutically acceptable salts thereof and pharmaceutical compositions containing then are useful in treating MHC class II dependent T-cell method autoimmune or inflammatory diseases, such as rheumatoid arthritis.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P—R1—R2—R3—R4, in which P, R1, R2, R3 and R4 have various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell medicated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P-AA I -AA 2 -AA 3 -AA 4 -AA 5 -AA 6 -AA 7 -AA 8 -Q, in which P, AA 1, AA 2, AA 3 , AA 4, AA 5, AA 6, AA 7, AA 8, and Q have the various meanings defined herein and their pharmaceutically accentable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P—R1—R2—R3—R4, in which P, R1, R2, R3 and R4 have various meanings defined herein, and their pharmaceutically salts, and pharmaceutically compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell medicated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I), P—R1—R2—R3—R4, in which P, R1, R2, R3, and R4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: The invention concerns pharmacologically useful peptide derivatives of the formula (I): P-AA1-AA2-AA3-AA4-AA5-AA6-AA7-AA8-Q, and pharmaceutically acceptable salts thereof, wherein either AA3 together with AA4, or AA4 together with AA5, or AA6 together with AA7 form a group of formula (II): in which Ra is selected from hydrogen and (1-4C)alkyl, and the remainder of AA1, AA2, AA3, AA4, AA5, AA6, AA7, and AA8 are L-amino acid residues; P is a hydrophobic residue; and Q is OH, NH2 or NRcRd. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds, and pharmaceutical compositions containing them, in treating MHC class II dependent T-cell mediated autoimmllne or inflammatory diseases, such as rheumatoid arthritis.

Abstract: The invention concerns pharmaceutically useful peptide derivatives of the formula (I): P--R.sup.1 --R.sup.2 --R.sup.3 --R.sup.4, in which P, R.sup.1, R.sup.2, R.sup.3, and R.sup.4 have the various meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel peptide derivatives are of value in treating MHC class II dependent T-cell mediated autoimmune or inflammatory diseases, such as rheumatoid arthritis. The invention further concerns processes for the manufacture of the novel peptide derivatives and the use of the compounds in medical treatment.

Abstract: A process for the solid phase synthesis of peptides containing a C-terminal aza-amino acid, for example the decapeptide goserelin, which comprises:(i) reacting an active ester or imidazolide of an N-protected aza-amino acid either with an appropriate reactive solid support in the case of the synthesis of a peptide containing a C-terminal aza-amino acid, or with a peptide which is attached to a solid support in the case of the synthesis of a peptide containing a non-C-terminal aza-amino acid;(ii) carrying out further conventional solid phase peptide synthesis steps to add sequentially further amino acids, to form a peptide with the required amino acid sequence bound to the solid support;(iii) cleaving the peptide from the solid support, and optionally(iv) reacting the product so formed with hydrazine to remove any acyl groups which have been formed on serine, arginine, tyrosine, threonine or hydroxyproline during the synthesis.

Abstract: The invention releates to a polypeptide of formula IR.sup.1 --CO--A.sup.1 --A.sup.2 --A.sup.3 A.sup.3 --A.sup.4 --A.sup.5 --A.sup.6 --Qwherein each of the generic terms is disclosed in full in the specification and includesR.sup.1 is a 5- or 6-membered unsaturated heterocyclic ring which contains one, two or three nitrogen atoms, which ring may optionally bear one or two substituents; a.sup.1 is a direct link to A.sup.2 ; or is His or D-His; A.sup.2 is Trp or MeTrp; A.sup.3 is Ala or MeAla; A.sup.4 is Val; A.sup.5 is Gly or D-Ala; A.sup.6 is His or Lys(Z); and Q is a group of the formula --A.sup.7.R.sup.2 in which A.sup.7 is Leu or LeMeu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino.The compounds possess antagonist properties against bombesin-like peptides and are of value in treatment of malignant disease in warm-blooded animals.

Abstract: The invention relates to a polypeptide of formula I:R.sup.1 -A.sup.1 -A.sup.2 -A.sup.3 -A.sup.3 -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.9 -Qwherein each of the generic terms is disclosed in full in the specification and includes: R.sup.1 is (2-6C)alkanoyl or (1-4C)alkoxycarbonyl; A.sup.1 is a direct link to A.sup.2, or is Gly or Arg; A.sup.2 is a direct link to A.sup.3, or is Gly or Pro; A.sup.3 is a direct link to A.sup.4, or is Lys or Lys(Z); A.sup.4 is His or D-His; A.sup.5 is Trp or MeTrp; A.sup.6 is Ala or MeAla; A.sup.7 is Val or MeVal; A.sup.8 is Gly or Sar; A.sup.9 is His or MeHis; and Q is a group of the formula -A.sup.10.R.sup.2 in which A.sup.10 is Leu or D-Leu and R.sup.2 is hydroxy, amino, (1-3C)alkylamino or (1-3C)alkoxy; or Q is (1-6C)alkoxy or (1-10C)alkylamino; provided that when R.sup.1 is acetyl and -A.sup.4 -A.sup.5 -A.sup.6 -A.sup.7 -A.sup.8 -A.sup.9 -Q is -His-Trp-Ala-Val-Gly-His-Leu-NH.sub.2 then -A.sup.1 -A.sup.2 -A.sup.3 - is not a direct link to His.

Abstract: Compounds of the formula: ##STR1## wherein R.sup.1 stands for an alk-2-enyl radical of not more than 5 carbon atoms or a furylmethyl radical, R.sup.2 stands for an alk-2-enyl or alkyl radical of not more than 5 carbon atoms or a furylmethyl radical, >N--A, B, D, E and F stand for defined amino acid or aza-amino-acid residues, and in particular one or both of B and D stand(s) for an amino acid residue of the formula --NH.C(1-3C alkyl)(1-3C alkyl).CO-- or a similar residue, and X stands for --OR.sup.7 or --NR.sup.7 R.sup.8, wherein R.sup.7 and R.sup.8, which may be the same or different, stand for hydrogen or a (1-4C)alkyl radical, and wherein the linkages are all conventional peptide linkages or in the case of D-E the peptide linkage is replaced by the group --CH.sub.2 S--, and pharmaceutically-acceptable salts thereof. Processes for the manufacture of the compounds. Pharmaceutical compositions comprising one of the compounds and a pharmaceutically-acceptable diluent or carrier.